Refining Risk Assessment in C9orf72-Associated Amyotrophic Lateral Sclerosis/Frontotemporal dementia: A Bayesian Approach

Amyotrophic lateral sclerosis (Amyotrophic Lateral Sclerosis) and frontotemporal dementia (Frontotemporal dementia) are devastating neurodegenerative diseases. A significant proportion of cases are linked to a hexanucleotide repeat expansion in the C9orf72 gene, making it the most common known genetic cause of both conditions. Genetic counseling plays a crucial role in informing families about their risk, particularly for individuals with a family history of the disease.

Currently, children of C9orf72 mutation carriers are often informed that they have a 50% chance of inheriting the mutation. While technically correct based on Mendelian inheritance, this figure doesn't account for a critical factor: age-related penetrance. Penetrance refers to the likelihood that someone carrying a disease-causing gene will actually develop the disease. In the case of C9orf72-related Amyotrophic Lateral Sclerosis/Frontotemporal dementia, penetrance increases with age, with the highest risk period centered around 58 years old. This means that simply knowing you carry the mutation doesn't tell the whole story about your personal risk.

The study described here addresses this limitation by developing a more refined method for calculating risk. The researchers employed a Bayesian approach, a statistical method that updates probabilities based on new evidence. In this context, the "evidence" is the individual's age and family history. By incorporating age-related penetrance data, the researchers developed a model to calculate the probability of both carrying the C9orf72 mutation and developing Amyotrophic Lateral Sclerosis/Frontotemporal dementia within a specific timeframe. This approach is particularly relevant for asymptomatic relatives, including children, siblings, grandchildren, and niblings of mutation carriers.

Key Components and Their Interrelation:

• C9orf72 Hexanucleotide Repeat Expansion: The underlying genetic cause being investigated.
• Age-Related Penetrance: The crucial factor that modifies the simple Mendelian risk assessment.
• Bayesian Approach: The statistical method used to integrate age-related penetrance into risk calculations.
• Risk Calculation for Asymptomatic Relatives: The specific application of the model, focusing on individuals who have not yet developed symptoms.
• Online Simulator: A practical tool developed to make these complex calculations accessible to clinicians and families.

Significance, Importance, Timeliness, and Relevance:

This work is significant because it moves beyond the simplified 50% risk figure, providing a more personalized and accurate risk assessment for individuals at risk of C9orf72-related Amyotrophic Lateral Sclerosis/Frontotemporal dementia. This is important because it can inform decisions about genetic testing and potentially influence lifestyle choices or participation in clinical trials. The timing is relevant as genetic testing for C9orf72 is becoming more widespread, increasing the need for nuanced interpretation of results. The relevance is high for families affected by Amyotrophic Lateral Sclerosis/Frontotemporal dementia, as it offers a more realistic understanding of their individual risk profiles.

Usefulness for Disease Management and Drug Discovery:

While this study doesn't directly lead to new treatments, it has implications for disease management and drug discovery:

• Improved Genetic Counseling: More accurate risk assessments can empower individuals to make informed decisions about genetic testing, family planning, and proactive healthcare.
• Clinical Trial Recruitment: Refined risk stratification could be used to identify individuals at higher risk of developing the disease, making them ideal candidates for preventative clinical trials.
• Understanding Disease Mechanisms: By more accurately identifying individuals who will develop the disease, researchers can better study the early stages of disease progression and identify potential therapeutic targets.

Originality:

The study provides original information beyond the obvious. While the concept of age-related penetrance is known, this research provides a concrete, mathematically sound method for incorporating it into risk calculations. The development of an online simulator further enhances the practical utility of the findings. The novelty lies in the application of a Bayesian framework to refine risk estimates in C9orf72-related Amyotrophic Lateral Sclerosis/Frontotemporal dementia, offering a more sophisticated and personalized approach compared to the standard Mendelian risk assessment.

Comparison to the State of the Art:

Current genetic counseling practices often rely on the simplified 50% risk figure. While some clinicians may qualitatively discuss the impact of age, this study provides a quantitative framework for incorporating age-related penetrance into risk assessment. Other research has focused on identifying genetic modifiers of disease risk, but this study focuses on a readily available and easily quantifiable factor: age.

Conclusion:

This study represents a valuable contribution to the field of Amyotrophic Lateral Sclerosis/Frontotemporal dementia genetics. By providing a more refined and personalized approach to risk assessment, it has the potential to improve genetic counseling, inform clinical trial recruitment, and ultimately contribute to a better understanding of the disease. The online simulator makes this complex information accessible to clinicians and families, further enhancing its practical impact. While not a direct path to new therapies,

Read the original article on medRxiv

Significance of the Topic: The topic of the text revolves around the potential relationship between antihypertensive medications, specifically angiotensin-converting enzyme (ACE) inhibitors, and the risk of Alzheimer's disease (Alzheimer's disease), a prevalent form of dementia. The significance of this topic lies in the fact that Alzheimer's disease affects millions of people worldwide, and identifying potential risk factors and therapeutic targets is crucial for managing and preventing the disease.

Importance: This research is important for several reasons:

1. High prevalence of antihypertensive medications: Over 60% of individuals aged 65 or older in the USA take antihypertensive medications, making it a critical concern to evaluate their potential impact on Alzheimer's disease risk.
2. Insidious development of Alzheimer's disease: Alzheimer's disease develops over decades, effectively precluding clinical trials of antihypertensive drug effects on Alzheimer's disease risk, making observational studies and experimental models essential for understanding the relationship between ACE inhibitors and Alzheimer's disease risk.
3. Potential therapeutic target: The identification of ACE as a viable therapeutic target for Alzheimer's disease and other tau-related neurodegenerative conditions offers new avenues for developing effective treatments.

Timeliness: The text is timely given the current concerns about the increasing prevalence of Alzheimer's disease and the need for innovative approaches to prevent and manage the disease. The research also highlights the importance of carefully tailored antihypertensive strategies to prevent dementia risk, which is particularly relevant in the context of aging populations.

Relevance: The text is relevant to various stakeholders, including:

1. Researchers: The study provides new insights into the relationship between ACE inhibitors and Alzheimer's disease risk, which can inform future research on the development of effective treatments.
2. Clinicians: The findings have implications for the management of hypertension and the prevention of dementia risk, particularly in older adults.
3. Policy-makers: The study highlights the need for carefully tailored antihypertensive strategies to prevent dementia risk, which has implications for healthcare policy and resource allocation.

Analysis of the text: The text reports a comprehensive study that employed a triangulation approach, combining large-scale human genetics, population-based study, and rigorous experimental models, to investigate the relationship between ACE inhibitors and Alzheimer's disease risk. The study identified that ACE inhibitors were associated with increased Alzheimer's disease risk, while other antihypertensive classes were not. The findings were validated through multi-omics Mendelian randomization analyses, cohort studies, and experimental models.

Insights on usefulness for disease management or drug discovery: The study provides valuable insights for disease management and drug discovery:

1. New therapeutic target: The identification of ACE as a viable therapeutic target for Alzheimer's disease and other tau-related neurodegenerative conditions offers new avenues for developing effective treatments.
2. Tailored antihypertensive strategies: The study highlights the importance of carefully tailored antihypertensive strategies to prevent dementia risk, which has implications for healthcare policy and resource allocation.
3. Experimental models: The study demonstrates the utility of experimental models, such as P301S tau transgenic mice and human iPSC-derived neurons, in validating the findings and providing mechanistic insights into the relationship between ACE inhibition and Alzheimer's disease risk.

Original information beyond the obvious: While the study builds on existing knowledge, the text provides original insights into the relationship between ACE inhibitors and Alzheimer's disease risk. The findings challenge the conventional view that ACE inhibitors are beneficial for cardiovascular health by suggesting that they may also increase Alzheimer's disease risk. The study's use of multi-omics Mendelian randomization analyses, cohort studies, and experimental models provides a robust and comprehensive understanding of the relationship between ACE inhibitors and Alzheimer's disease risk, which offers new avenues for disease management and drug discovery.

Comparison with the state of art: The study contributes to the growing body of evidence on the relationship between antihypertensive medications and Alzheimer's disease risk. While previous studies have reported various associations between antihypertensive medications and Alzheimer's disease risk, this study provides a more comprehensive understanding of the relationship between ACE inhibitors and Alzheimer's disease risk, underscoring the importance of carefully tailored antihypertensive strategies to prevent dementia risk.

Read the original article on medRxiv

Investigating the Role of Bassoon Mutations in Parkinson's Disease Motor Dysfunction

Parkinson's Disease (Parkinson disease) is a neurodegenerative disorder primarily known for its motor symptoms, including rigidity, tremor, bradykinesia (slowness of movement), and postural instability. While current treatments can manage some of these symptoms, gait and balance impairments, particularly freezing of gait (FOG), remain a significant challenge for many patients. Understanding the underlying causes of these specific motor deficits is crucial for developing more effective therapies.

This study investigates the potential role of rare mutations in the Bassoon (BSN) gene in contributing to motor dysfunction in Parkinson disease patients. Bassoon is a large protein located at the presynaptic active zone, a specialized region where neurotransmitters are released. It acts as a scaffold protein, organizing the machinery necessary for efficient neurotransmission.
Given its critical role in synaptic function, disruptions in Bassoon could plausibly contribute to the pathophysiology of neurological disorders.

Significance, Importance, Timeliness, and Relevance:

• Significance: The study is significant because it explores a novel genetic factor potentially contributing to a specific and debilitating aspect of Parkinson disease: gait and balance impairments. While much Parkinson disease research focuses on alpha-synuclein, exploring other potential genetic contributors broadens authors' understanding of the disease's complexity.
• Importance: Identifying genetic risk factors like BSN mutations is important for several reasons. It can improve diagnostic accuracy, potentially leading to earlier intervention. It also provides valuable insights into the underlying disease mechanisms, which can inform the development of targeted therapies.
• Timeliness: The study is timely because of the growing recognition of the heterogeneity of Parkinson disease and the need for personalized medicine approaches. Identifying specific genetic subtypes within the Parkinson disease population allows for more tailored treatment strategies.
• Relevance: The study is highly relevant to the Parkinson disease field, particularly for researchers and clinicians interested in the genetic basis of motor dysfunction and the development of novel therapeutic targets.

Analysis of Study Components:

• Introduction: Clearly sets the stage by highlighting the unmet need for effective treatments for gait and balance impairments in Parkinson disease and introduces Bassoon as a potential player.
• Methods: Describes the study design, including the patient cohort (early-onset Parkinson disease patients from South Asia), the definition of "rare" variants, and the use of computational tools to predict the impact of the identified mutations. The inclusion of a control group is essential for drawing meaningful conclusions.
• Results: Presents the key findings: a statistically significant association between BSN mutations and increased FOG, shuffling gait, and falls. The clustering of rare mutations in a specific region of the Bassoon protein (C-terminal) is also noteworthy, suggesting a critical functional domain. The identification of seven likely pathogenic variants based on computational predictions provides further support for the role of BSN mutations in Parkinson disease.
• Conclusion: Summarizes the main findings and proposes a potential link between Bassoon dysfunction and the convergence of synucleinopathies (like Parkinson disease) and tauopathies (like Progressive Supranuclear Palsy), suggesting a broader role for Bassoon in neurodegenerative diseases.

Relationship Between Study Components:

The study components are logically connected. The introduction establishes the problem and the rationale for investigating Bassoon. The methods describe how the study was conducted to address the research question. The results present the findings, and the conclusion interprets these findings in the context of existing knowledge and proposes future directions.

Usefulness for Disease Management and Drug Discovery:

This study has potential implications for both disease management and drug discovery:

• Disease Management: Identifying BSN mutations as a risk factor for specific motor symptoms could lead to genetic screening in Parkinson disease patients, particularly those with early-onset disease and prominent gait and balance problems. This could inform prognosis and potentially guide treatment decisions.
• Drug Discovery: Bassoon could represent a novel therapeutic target for Parkinson disease. Understanding the specific mechanisms by which BSN mutations contribute to motor dysfunction could lead to the development of drugs that restore Bassoon function or compensate for its deficiency.

Originality of Information:

The study provides original information beyond the obvious. While the role of synaptic dysfunction in Parkinson disease is well-established, the specific involvement of BSN mutations in gait and balance impairments is a novel finding. The identification of specific pathogenic variants and the proposed link to tauopathies add further value to the study.

Comparison with the State of the Art:

While previous research has implicated Bassoon in other neurological disorders, its role in Parkinson disease, particularly in relation to gait and balance, has not been extensively studied. This study contributes to the growing body of evidence suggesting that synaptic dysfunction is a critical factor in Parkinson disease pathogenesis and highlights the potential of Bassoon as a therapeutic target. The study builds upon existing knowledge by providing specific genetic and functional insights into the role of Bassoon in Parkinson disease.

Overall Assessment:

This study provides valuable insights

Read the original article on medRxiv